Unceasing clinical trials to discover potential orally injectable drugs is likely to spur market growth prospects
Unceasing clinical trials to discover potential orally injectable drugs is likely to spur market growth prospects
Fact.MR, Rockville MD: Award winning market research company Fact.MR’s ongoing global von hippel-lindau (VHL) market study forecasts a positive outlook for FY 2021-22, attributable to such key factors as rising prevalence of VHL-related hemangioblastomas, increased funding for oncology research and efforts to discover novel treatment alternatives, including molecular diagnostics.
It is estimated that about 1 in 30,000 people is afflicted with VHL, out of which nearly 10% possess a de novo mutation. About 97% of the symptoms of VHL manifest themselves at the age of 65. According to the National Organization for Rare Disorders, there are nearly 10,000 cases across the US, and 200,000 cases worldwide. People with VHL may experience tumors or cysts in up to ten body parts, including the brain, eyes and kidneys.
Based on such high incidence rates, research and funding for finding potential treatments and cures is inclining. As per W.H.O’s Global Action Plan for the prevention and control of NCDs (2013-2020), countries globally have committed to developing effective frameworks to fund cancer research programs, which is likely to incline the scope for VHL diagnostics in the future.
“Dearth of adequate treatment approaches is spurring key pharmaceutical corporations to invest in novel therapeutic approaches to find an effective cure for VHL induced cancers, heightening growth prospects,” says a Fact.MR analyst.
Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=5289
Key Takeaways from Fact.MR’s Von Hippel-Lindau Market Study
- By tumor site, VHL screening for the brain is likely to remain dominant, amid high prevalence rate of cerebellar hemangioblastomas
- Based on diagnosis, MRI scanning is expected to acquire significant momentum, attributed to ease of differentiation
- Hospitals to be the primary end-users of VHL screening equipment, diagnostic centers surging in popularity
- US to experience high uptake amid rising prevalence of de-novo VHL syndrome cases
- Surging renal cell carcinoma cases bolstering VHL screening across the UK
- Advanced oncology research facilities to broaden expansion prospects for Germany and France
- Manufacturers are likely to find Denmark the most opportunistic market, amid its top position regarding VHL syndrome prevalence
- India and China to emerge as highly opportunistic markets across the Asia-Pacific region
Von Hippel-Lindau Market- Prominent Drivers
- Accelerating healthcare expenditure for funding cancer research likely to augment VHL market growth prospects
- Key pharmaceutical companies are initiating numerous clinical trials to develop orally administered therapies, stimulating growth
- Rapid advancements in molecular diagnostics are expected with regard to more effective VHL syndrome treatment
Von Hippel-Lindau Market- Key Restraints
- Non-availability of existing drug candidates to treat the syndrome is compounding its global burden, restraining growth
- Prolonged clinical trials duration for future drug candidates is restricting effective treatment for VHL syndrome across key geographies
Discover more about the von hippel-lindau market with figures and data tables, along with the table of contents. You will also find detailed market segmentation on https://www.factmr.com/report/5289/von-hippellindau-market
Competitive Landscape
Fact.MR’s von hippel-lindau market study has profiled the following prominent players: Eli Lilly and Company, Bedford Laboratories, DNAtrix Inc., Astellas US Holding Inc., Candel Therapeutics, Burzynski Research Institute Inc., Cellectar Biosciences Inc. and Direct Therapeutics Inc. among others. Offering advanced diagnosis remains the core strategy for the aforementioned pharmaceutical giants.
For instance, Eli Lilly and Company is actively providing community health screenings for breast and cervical cancers in Kenya through AMPATH, the company’s primary global health partner. Through product and financial donations, Lilly and the Lilly Foundation support the AMPATH consortium, including its oncology center and mobile screening program.
Likewise, Cellectar Biosciences Inc. is currently working on its CLR 131 small-molecule pyruvate dehydrogenase complex (PDC) to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells. This candidate is specifically designed for curing various types of pediatric cancers, and is expected to address patients inheriting the von hippel-lindau gene in the future.
More Insights on the Von Hippel-Lindau Market
Fact.MR, in its new offering, brings to fore an unbiased analysis of the global von hippel-lindau market, presenting historical demand data (2016-2020) and forecast statistics for the period, 2021-2031. The study divulges compelling insights on the von hippel-lindau market based on tumor site (brain, spine, eyes, kidneys, adrenal glands, pancreas, liver, lungs, inner ears and reproductive tract), diagnosis (MRI scan, CT scan and others), and end-user (hospitals, clinics, diagnostic centers and others) across seven major regions (North America, Latin America, Europe, South Asia, East Asia, Oceania and Middle East & Africa).
Request For No-Obligation Table Of Content
https://www.factmr.com/connectus/sample?flag=T&rep_id=5289
Explore Fact.MR’s Coverage on the Healthcare Domain
Subcutaneous Biologics Market: Explore Fact.MR’s incumbent market study on subcutaneous biologics, providing an insightful coverage on prominent growth dynamics for the upcoming forecast period. Market statistics have been provided by virtue of detailed segmental mapping across prominent geographies, as well as details about the competitive landscape.
Ventricular Restoration Systems Market: The ongoing ventricular restoration systems market study being conducted by Fact.MR provides insights concerning growth parameters expected to present themselves for the 2021-2031 forecast period. The study intends to outline prominent statistics across key segments spread over important geographical locations, along with an in-depth competitive landscape.
Preimplantation Genetic Testing Market: The objective of this Fact.MR report is to analyze the global preimplantation genetic testing market for the forthcoming decade and provide readers an unbiased and accurate analysis. Medical device manufacturers, research institutes, and raw material suppliers in the global preimplantation genetic testing market can benefit from the analysis offered in this report.
About Fact.MR
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E: sales@factmr.com
Follow Us: LinkedIn | Twitter
Market Intelligence Services: Marketngage.com
Source: Fact.MR